1 |
Chan TA, Glockner S, Yi JM, et al (2008). Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict poor prognosis. PLoS Med, 5, 823-39.
|
2 |
Christoph F, Hinz S, Kempkensteffen C, et al (2007). A gene expression profile of tumor suppressor genes commonly methylated in bladder cancer. J Cancer Res Clin Oncol, 133, 343-9.
DOI
|
3 |
Cooks T, Harris CC (2014). p53 Mutations and Inflammation-Associated Cancer Are Linked through TNF Signaling. Mol Cell, 56, 611-2.
DOI
|
4 |
Gao SY, Li J, Qu XY, Zhu N, Ji YB (2014). Downregulation of Cdk1 and cyclinB1 expression contributes to oridonininduced cell cycle arrest at G2/M phase and growth inhibition in SGC-7901 gastric cancer cells. Asian Pac J Cancer Prev, 15, 6437-41.
DOI
|
5 |
Hao Y, Chun A, Cheung K, Rashidi B, Yang X (2008). Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem, 283, 5496-509.
DOI
|
6 |
Hisaoka M, Tanaka A and Hashimoto H (2002). Molecular alterations of h-warts/LATS1 tumor suppressor in human soft tissue sarcoma. Lab Invest, 82, 1427-35.
DOI
|
7 |
Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G and Lu D (2006). Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neuroscience Res, 56, 450-58.
DOI
|
8 |
Kanherkar RR, Bhatia-Dey N, Makarev E, Csoka AB (2014). Cellular reprogramming for understanding and treating human disease. Front Cell Dev Biol, 12, 67.
|
9 |
Lin H, Fang L, Lin D (2014). Association of cyclin D1 variants with head and neck cancer susceptibility: evidence from a meta-analysis. Asian Pac J Cancer Prev, 15, 5645-51.
DOI
|
10 |
Liu H, Xing Y, Yang S, Tian D (2011). Remarkable difference of somatic mutation patterns between oncogenes and tumor suppressor genes. Oncol Rep, 26, 1539-46.
|
11 |
Mak AS (2014). p53 in cell invasion, podosomes, and invadopodia. Cell Adh Migr, 8, 205-14.
DOI
|
12 |
McLaughlin SK, Olsen SN, Dake B, et al (2013). The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell, 24, 365-78.
DOI
|
13 |
Mehta DT, Annamalai T, Ramanathan A (2014). Lack of mutations in protein tyrosine kinase domain coding exons 19 and 21 of the EGFR gene in oral squamous cell carcinomas. Asian Pac J Cancer Prev, 15, 4623-7.
DOI
|
14 |
Mishra A, Meherotra R (2014). Head and neck cancer: global burden and regional trends in India. Asian Pac J Cancer Prev, 15, 537-50.
DOI
ScienceOn
|
15 |
Moran A, Fernandez-Marcelo T, Carro J, et al (2012). Methylation profiling in non-small cell lung cancer: clinical implications. Int J Oncol, 40, 739-46.
|
16 |
Peters I, Dubrowinskaja N, Abbas M, et al (2014). DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies. PLoS One, 9, 91440.
DOI
|
17 |
Rivlin N, Brosh R, Oren M, Rotter V (2011). Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer, 2, 466-74.
DOI
ScienceOn
|
18 |
Sharma S, Sambyal V, Guleria K, et al (2014). TP53 polymorphisms in sporadic North Indian breast cancer patients. Asian Pac J Cancer Prev, 15, 6871-9
DOI
|
19 |
Vallot C, Stransky N, Bernard-Pierrot I, et al (2011). A novel epigenetic phenotype associated with the most aggressive pathways of bladder tumor progression. J Natl Cancer Inst, 103, 47-60.
DOI
|
20 |
Takahashi Y, Miyoshi Y, Takahata C, et al (2005). Down regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologicall aggressive phenotype in human breast cancers. Cancer Res, 11, 1380-5.
|
21 |
Visser S, Yang X (2010). LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle, 9, 3892-903.
DOI
|
22 |
Marcinkiewicz KM, Gudas LJ (2014). Altered histone mark deposition and DNA methylation at homeobox genes in human oral squamous cell carcinoma. J Cell Physiol, 229, 1405-16.
DOI
|
23 |
Yang H, Zhong Y, Peng C, Chen JQ, Tian D (2010). Important role of indels in somatic mutations of human cancer genes. BMC Med Genet, 11, 128.
DOI
|
24 |
Bhatia V, Goel MM, Makker A, et al (2014). Promoter region hypermethylation and mRNA expression of MGMT and p16 genes in tissue and blood samples of human premalignant oral lesions and oral squamous cell carcinoma. Biomed Res Int, 2014, 248419.
|
25 |
Adduri RS, Katamoni R, Pandilla R, et al (2014). TP53 Pro72 allele is enriched in oral tongue cancer and frequently mutated in esophageal cancer in India. PLoS One, 9, 114002.
DOI
|
26 |
Asokan GS, Jeelani S, Gnanasundaram N (2014). Promoter hypermethylation profile of tumour suppressor genes in oral leukoplakia and oral squamous cell carcinoma. J Clin Diagn Res, 8, 9-12.
|
27 |
Aylon Y, Oren M (2011). New plays in the p53 theater. Curr Opin Genet Dev, 21, 86-92.
DOI
|
28 |
Bothos J, Tuttle RL, Ottey M, Luca FC, Halazonetis TD (2005). Human LATS1 is a mitotic exit network kinase. Cancer Res, 65, 6568-75.
DOI
|